IP Library › Granted Patent US 9,278,083
Granted Patent B2
US 9,278,083 · App. 14/596,034 · Granted Mar 8, 2016

Methods for purifying trans-(−)-Δ

Inventors: Arie L. Gutman (Haifa, IL); Marina Etinger (Nesher, IL); Irina Fedotev (Haifa, IL); Ram Khanolkar (Coventry, RI); Gennady A. Nisnevich (Haifa, IL); Boris Pertsikov (Nesher, IL); Igor Rukhman (Yokneam, IL); Boris Tishin (Haifa, IL)
Assignee: SVC Pharma LP
A61K31/352C07D311/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,278,083
App. No.
14/596,034
Granted
Mar 8, 2016
Kind
B2
Abstract

Methods for making trans-(−)-Δ 9 -tetrahydrocannabinoI and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinoI composition is prepared by allowing a composition comprising (±)-Δ 9 -tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

Claims (18)

1. A trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least 99.0% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol and less than 0.05% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

2. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 1 , comprising at least 99.5% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

3. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 1 , comprising at least 99.9% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

4. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 1 , wherein the composition comprises up to about 99.95% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

5. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 1 , wherein the composition comprises up to about 99.98% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

6. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 2 , wherein the composition comprises up to about 99.95% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

7. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 2 , wherein the composition comprises up to about 99.98% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

8. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 3 , wherein the composition comprises up to about 99.95% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

9. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 3 , wherein the composition comprises up to about 99.98% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of cannabinoids.

10. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 1 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

11. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 2 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

12. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 3 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

13. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 4 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

14. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 5 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

15. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 6 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

16. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 7 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

17. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 8 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

18. The trans-(−)-Δ 9 -tetrahydrocannabinol composition of claim 9 , wherein the composition comprises less than 0.01% of Δ 9 -tetrahydrocannabinol acid based on the total amount of cannabinoids.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: GUTMAN, ARIE L.; NISNEVICH, GENNADY A.; RUKHMAN, IGOR; TISHIN, BORIS; ETINGER, MARINA; FEDOTEV, IRINA; PERTSIKOV, BORIS; KHANOLKAR, RAM
To: EURO-CELTIQUE S.A.
Reel/Frame 036859/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2015
From: EURO-CELTIQUE S.A.
To: SVC PHARMA LP
Reel/Frame 036859/0598 →
Continuity (4)
Division 13774955 · Feb 22, 2013
Continuation 11791415
Provisional Application 60630556 · Nov 22, 2004
Related Publication 20150126596A1 · May 7, 2015